Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Unknown 6Recruiting 5Withdrawn 4Completed 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoplasms 1Hematologic Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Unknown × Interventional × Thymalfasin × Clear all
NCT05790447 2023-03-30

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

NCT02545751 2017-11-28

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

Hangzhou Cancer Hospital

Phase 2 Unknown
29 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT02787447 2016-11-25

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

First People's Hospital of Hangzhou

Phase 2 Unknown
46 enrolled
Thoracic

Adenocarcinoma of Lung

NCT02906150 2016-09-19

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

SciClone Pharmaceuticals

Phase 2 Unknown
140 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

SciClone Pharmaceuticals

Phase 1/2 Unknown
188 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00580450 2007-12-24

Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies

University Of Perugia

Phase 1/2 Unknown
9 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡